AKT1 and breast carcinoma: Formononetin has also been shown to inhibit the upstream signals of the PI3K–AKT pathway by downregulating the expression of the insulin-like growth factor receptor (IGF-1R) in human breast cancer cells (Chen et al., 2011; Chen et al., 2013).